Gemini Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMTX research report →
Companywww.geminitherapeutics.com
Gemini Therapeutics, Inc. , a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
- IPO
- 2020
- Employees
- 24
- HQ
- Cambridge, MA, US
Price Chart
Performance & Tape
- 52W High
- $24.70
- 52W Low
- $1.35
- 50D MA
- $16.65
- 200D MA
- $15.80
- Beta
- 0.00
- Avg Volume
- 22.36K
Get TickerSpark's AI analysis on GMTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 10, 24 | Bitterman Kevin | sell | 20,000 |
| Jan 10, 24 | Atlas Venture Fund X, L.P. | sell | 30,000 |
| Jan 10, 24 | Atlas Venture Fund X, L.P. | sell | 20,000 |
| Dec 29, 23 | Quisel John D | other | 2,700 |
| Dec 29, 23 | Quisel John D | other | 2,700 |
| Dec 27, 23 | Bryce Joanne | other | 3,000 |
| Dec 27, 23 | Bryce Joanne | other | 3,000 |
| Dec 18, 23 | ORBIMED ADVISORS LLC | other | 1,724 |
| Dec 18, 23 | ORBIMED ADVISORS LLC | other | 1,724 |
| Dec 18, 23 | ORBIMED ADVISORS LLC | sell | 1,724 |
Our GMTX Coverage
We haven't published any research on GMTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GMTX Report →